^
    Back
    Association details:
    Biomarker:KIT D816V
    Cancer:Acute Myelogenous Leukemia
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Blood
    Title:

    Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

    Excerpt:
    Significantly, dasatinib inhibits the kinase activity of KITD816V with comparable efficiency to wild-type KIT (IC50 of 37 and 79 nM, respectively) in in vitro kinase experiments, whereas the ability of imatinib to inhibit KITD816V kinase activity is highly impaired.
    DOI:
    https://doi.org/10.1182/blood-2005-10-3969
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Leuk Res
    Title:

    Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V

    Excerpt:
    Dasatinib has in vitro and in vivo efficacy in SM-AML patients with KIT(D816V) mutation.
    Secondary therapy:
    cytarabine
    DOI:
    10.1016/j.leukres.2008.09.027